
Mid-Cycle Review Memorandum(2), April 16, 2009 - Anascorp

 

 

DATE 
April 16, 2009
 
 
FROM 
Robert Wesley, Bioresearch Monitoring Branch, HFM-664
Division of Inspections and Surveillance
Office of Compliance and Biologics Quality 


 

THROUGH
 
Patricia Holobaugh, BIMO Branch Chief, HFM-664 
TO 
Debbie Cordaro, HFM-380, RPM
 
SUBJECT 
Mid-Cycle Review Memo 
Sponsor: Bioclon

Product: Scorpion Antivenin

BLA/ STN 125335/0 



 

INTERIM SUMMARY STATEMENT

 

-------------------------------------------------------------------------------------------------------------------------------------------Information withheld per the Privacy Act------------.

 

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Information withheld per the Privacy Act--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------.

 

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Information withheld per the Privacy Act-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------.

 

-------------------------------Information withheld per the Privacy Act-----------------------------------------------------------------------------------------------------------------------------------.